Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-021358
Filing Date
2025-05-01
Accepted
2025-05-01 09:22:18
Documents
97
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q xfor-20250331.htm   iXBRL 10-Q 1375836
2 EX-10.16 ex-1016compensationpolicyq.htm EX-10.16 15570
3 EX-31.1 ex-311q12025.htm EX-31.1 9253
4 EX-31.2 ex-312q12025.htm EX-31.2 9241
5 EX-32.1 ex-321q12025.htm EX-32.1 5446
  Complete submission text file 0001628280-25-021358.txt   8017840

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20250331.xsd EX-101.SCH 69320
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT xfor-20250331_cal.xml EX-101.CAL 68611
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xfor-20250331_def.xml EX-101.DEF 286031
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20250331_lab.xml EX-101.LAB 734079
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20250331_pre.xml EX-101.PRE 521065
100 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20250331_htm.xml XML 1051134
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38295 | Film No.: 25899905
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)